ArticleCancer discovery2021
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 156 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
156 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.
- Squalene Epoxidase: Its Regulations and Links with Cancers.International journal of molecular sciences · 2024Pooled it
- The immune phenotype of circulating tumor cells: from escape mechanisms to immunotherapy navigation.Biomarker research · 2026Review
- Review
- Pharmacological targeting of ferroptosis in cancer: mechanisms, tumor immunity, and translational challenges.Pharmacological reports : PR · 2026Review
- From Ferroptotic Stress to Stemness: TNT-Mediated EMT Plasticity in Cancer Progression.Stem cell reviews and reports · 2026Review
- Sterol regulatory element‑binding proteins: Master regulators of lipid metabolic reprogramming in cancer and emerging therapeutic targets (Review).Oncology reports · 2026Review
- Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).International journal of oncology · 2026Review
- Adherent-to-suspension transition modulates circulating tumor cell dynamics and metastatic potential in melanoma.Molecules and cells · 2026Article
- Translating ferroptosis into oncology: challenges, opportunities and future directions.Nature reviews. Clinical oncology · 2026Review
- Integrating spatial and single-cell transcriptomics analysis reveals MYCN-UBE2C-TFRC signaling endows ferroptosis resistance in neuroectodermal tumors.Science China. Life sciences · 2026Article
- Iron overload reprogramming lipid metabolism through the IRP1-SCAP axis in fibroblast-like synoviocytes aggravates bone destruction in rheumatoid arthritis.Experimental & molecular medicine · 2026Article
- Review
- Redox processes in the treatment of advanced skin cancers.Clinical & experimental metastasis · 2026Review
- Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma.Cell death & disease · 2026Article
- Lipids grease the chain of cancer progression.Trends in cancer · 2026Review
- GWAS SVatalog: a visualization tool to aid fine-mapping of GWAS loci with structural variations.Heredity · 2026Article
- Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026Review
- Silencing myeloid cell leukemia-1 improves apoptotic and ferroptotic responses in melanoma.European journal of medical research · 2026Article
- CBX3 confers ferroptosis resistance during blood-borne metastasis.Journal of hematology & oncology · 2026Article
- Reconstructing the metastatic journey: functional circulating tumor cells and disseminated tumor cells based models for translational oncology.Journal of experimental & clinical cancer research : CR · 2026Review
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 1 country.
Xin Hong *Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9671-0116
Whijae Roh *Broad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-7395-9939
Ryan J SullivanMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Keith H K WongCenter for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6578-0373
Ben S WittnerMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5657-9849
Hongshan GuoMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Taronish D DubashMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Moshe Sade-FeldmanMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Benjamin WesleyMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Elad HorwitzMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0361-3374
Genevieve M BolandMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7522-6173
Dieuwke L MarvinMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Todd BonesteelMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Chenyue LuMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7905-2078
François AguetBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0001-9414-300X
Risa BurrMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Samuel S FreemanBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0001-8285-0057
Laxmi ParidaDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7872-5074
Katherine CalhounMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Michelle K JewettMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Linda T NiemanMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0141-8308
Nir HacohenMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Anders M NäärMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
David T TingMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3261-2322
Mehmet TonerCenter for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Shannon L StottMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
Gad GetzMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0936-0753
Shyamala MaheswaranMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. dhaber@mgh.harvard.edu maheswaran@helix.mgh.harvard.edu.
Daniel A HaberMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts. dhaber@mgh.harvard.edu maheswaran@helix.mgh.harvard.edu.
Massachusetts General Hospital · USBroad Institute · USAlliance for Safe Kids · USHoward Hughes Medical Institute · US
Funding
Point-of care Microfluidics for Early Detection of CancerU01EB012493 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., TONER, MEHMET · 2010 to 2018
$19.6MBio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MModeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5MBenchmarking the Sensitivity and Specificity of the Herringbone Microfluidic Device for Rare Particle CaptureR01CA226871 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHED, BRIAN VALA, STOTT, SHANNON L · 2018 to 2023
$2.3MNCI NIH HHS R01 CA129933NCI NIH HHS R01 CA226871NHGRI NIH HHS T32 HG002295NIBIB NIH HHS P41 EB002503NIBIB NIH HHS U01 EB012493
Abstract
Circulating tumor cells (CTC) are shed by cancer into the bloodstream, where a viable subset overcomes oxidative stress to initiate metastasis. We show that single CTCs from patients with melanoma coordinately upregulate lipogenesis and iron homeostasis pathways. These are correlated with both intrinsic and acquired resistance to BRAF inhibitors across clonal cultures of
Indexed as
Biomarkers, TumorCells, CulturedDisease SusceptibilityFerroptosisGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansLipogenesisMelanomaMutationNeoplastic Cells, CirculatingSignal TransductionSingle-Cell AnalysisSterol Regulatory Element Binding Protein 2TransferrinBiomarkers, TumorSREBF2 protein, humanSterol Regulatory Element Binding Protein 2Transferrin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.